Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intracellular phospholipids are a diverse class of lipid molecules that constitute the fundamental structural framework of cellular and organelle membranes. They play a pivotal role in cell signaling, acting as precursors for secondary messengers like inositol trisphosphate (IP3) and diacylglycerol (DAG), which regulate cell growth, survival, and metabolism (Source: NIH, "Phospholipids and Cell Signaling"). In various diseases, including cancer and inflammatory disorders, the metabolism and distribution of these lipids are often altered, making them attractive targets for therapeutic intervention (Source: PubMed, PMID: 25614444). Drugs such as miltefosine and edelfosine exert their effects by interacting with these phospholipids to disrupt membrane-associated signaling or induce apoptosis in malignant cells (Source: PubChem, "Miltefosine"). Additionally, certain antibiotics like polymyxins target phospholipids to disrupt bacterial membrane integrity (Source: StatPearls, "Polymyxin B"). However, the therapeutic targeting of phospholipids is frequently complicated by drug-induced phospholipidosis, a condition where cationic amphiphilic drugs accumulate within lysosomes, potentially leading to organ toxicity (Source: FDA, "Drug-Induced Phospholipidosis"). Understanding the spatial and temporal dynamics of intracellular phospholipids is essential for developing selective therapies that minimize off-target effects on healthy cell membranes.
Drugs targeting intracellular phospholipids typically act by direct binding to membrane components, leading to the disruption of membrane integrity and permeability, or by interfering with phospholipid-mediated signaling pathways and metabolism. Some drugs also induce the accumulation of phospholipids within lysosomes, a process known as drug-induced phospholipidosis, by inhibiting lysosomal phospholipase activity or forming indigestible drug-lipid complexes.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intracellular phospholipids (PLs) (PLs).